Principal Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Principal Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,771	Closed	-$374K	–	2205
2025 Q3	$374K	Buy	5,771 +104	+2%	+$5.97K	﹤0.01%	2100
2025 Q2	$276K	Buy	+5,667	New	+$219K	﹤0.01%	2089
2024 Q3	–	Sell	-7,052	Closed	-$381K	–	2268
2024 Q2	$381K	Sell	7,052 -33,418	-83%	-$1.93M	﹤0.01%	2016
2024 Q1	$2.76M	Buy	+40,470	New	+$2.9M	﹤0.01%	1729
2022 Q4	–	Sell	-9,059	Closed	-$592K	–	2462
2022 Q3	$592K	Buy	9,059 +265	+3%	+$19.2K	﹤0.01%	1927
2022 Q2	$534K	Sell	8,794 -21	-0.2%	-$1.24K	﹤0.01%	2044
2022 Q1	$553K	Sell	8,815 -344	-4%	-$21.6K	﹤0.01%	2093
2021 Q4	$694K	Sell	9,159 -6,043	-40%	-$528K	﹤0.01%	2051
2021 Q3	$1.7M	Sell	15,202 -2,427	-14%	-$305K	﹤0.01%	1899
2021 Q2	$2.85M	Buy	17,629 +1,875	+12%	+$228K	﹤0.01%	1836
2021 Q1	$1.92M	Buy	+15,754	New	+$2.38M	﹤0.01%	1862

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GSK plc London $602M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Financial Group's CRSP Position: Q4 2025 in Review

Principal Financial Group sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 5,771 shares — an estimated $374K sold.

Principal Financial Group first reported a position in CRSP in Q1 2021 and held it in 11 quarters. The position peaked at $2.85M in Q2 2021. 480 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Principal Financial Group reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Principal Financial Group sold 5,771 CRISPR Therapeutics shares in Q4 2025, an estimated $374K.
Principal Financial Group first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 11 quarters.
Principal Financial Group's CRISPR Therapeutics position peaked at $2.85M in Q2 2021.
480 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Principal Financial Group's 13F filing for Q4 2025, filed 2 Feb 2026.